<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Argatroban: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Argatroban: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Argatroban: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8765" href="/d/html/8765.html" rel="external">see "Argatroban: Drug information"</a> and <a class="drug drug_patient" data-topicid="10966" href="/d/html/10966.html" rel="external">see "Argatroban: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F998934"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anticoagulant, Thrombin Inhibitor</span></li></ul></div>
<div class="block don drugH1Div" id="F56834723"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="268855ac-c424-450c-ab52-a51bfe383ea4">Heparin-induced thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia (HIT):</b> Very limited data available: <b>Note: </b>Required maintenance dose is highly variable between patients; frequent dosage adjustments required in critically ill patients and/or patients with liver impairment to maintain desired anticoagulant activity (Action 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Term Neonates: Continuous IV Infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose:</i> 0.75 mcg/kg/minute; measure aPTT after 2 hours; titrate to maintain aPTT in desired range; adjust in increments of 0.1 to 0.25 mcg/kg/minute if normal hepatic function. <b>Note:</b> Effects of liver impairment in neonates are unknown; however, lower doses have been used in infants and children with liver impairment (Radulescu 2017; Young 2011).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i> Measure aPTT 2 hours after any dose change and at least once daily; more frequent monitoring may be required based on clinical status; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value (depends on bleeding risk), not exceeding 100 seconds; adjust in increments of 0.1 to 0.25 mcg/kg/minute if normal hepatic function (Young 2011; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f1c93a4-9f0d-42aa-b239-e77884f28a00">Anticoagulation, mechanical circulatory support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticoagulation, mechanical circulatory support:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ventricular assist device (VAD) </i>(ACTION 2020): Very limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Dosing based on a consensus protocol; goal aPTT range determined by risk of bleeding and thrombosis and postoperative phase of care.</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: <i>Initial dose:</i> Continuous IV infusion: 0.5 mcg/kg/minute; consider a lower initial dose in the setting of liver impairment with baseline elevated INR; titrate to achieve target aPTT (See "Dose Adjustments to Achieve Target aPTT" table); usual dosage range: 1 to 5 mcg/kg/minute; doses up to 8 mcg/kg/minute have been used; maximum adult dose: 10 mcg/kg/minute.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Dose Adjustments to Achieve Target aPTT</b></p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>aPTT</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Argatroban titration</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Time to repeat aPTT<sup>a</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Consider more frequent aPTT monitoring based on clinical scenario.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Round dose up to closest second decimal (hundredth place).</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Recommendation in patient with normal hepatic function; in patients with significant hepatic impairment, hold infusion for 2 hours then recheck aPTT before restarting (see "Altered liver function").</p>
<p style="text-indent:0em;text-align:left;">Adapted from ACTION 2020.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥15 to 30 seconds below goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increase infusion by 25%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 to &lt;15 seconds below goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increase infusion by 15%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Within goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No change</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours; then daily after 2 consecutive aPTTs within goal range</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 to &lt;15 seconds above goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Decrease infusion by 15%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥15 to 30 seconds above goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Decrease infusion by 25%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;3× baseline or &gt;~120 seconds</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hold infusion for 15 minutes and decrease infusion by 30%<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 hours</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered liver function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heparin-induced thrombocytopenia: </i></p>
<p style="text-indent:-2em;margin-left:6em;">AST/ALT ≥3 times ULN:</p>
<p style="text-indent:-2em;margin-left:8em;">Term Neonates:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose: Continuous IV Infusion: Consider a lower initial dose in the setting of hepatic dysfunction (eg. 0.2 mcg/kg/minute) (Young 2011).</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: Measure aPTT 2 hours after any dose change and at least once daily; more frequent monitoring may be required based on clinical status; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value (depends on bleeding risk), not exceeding 100 seconds; adjust in increments of ≤0.05 mcg/kg/minute (Young 2011; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ventricular assist device (VAD):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: Continuous IV infusion (ACTION 2020):</p>
<p style="text-indent:-2em;margin-left:8em;">Baseline liver impairment:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose: Consider lower initial dose with known liver impairment and baseline elevated INR.</p>
<p style="text-indent:-2em;margin-left:8em;">Liver impairment during treatment:</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: Check aPTT and monitor closely.</p>
<p style="text-indent:-2em;margin-left:8em;">Significant liver impairment during treatment:</p>
<p style="text-indent:-2em;margin-left:10em;">aPTT &gt;3 times baseline or &gt;~120 seconds: Hold infusion for 2 hours then recheck aPTT before restarting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dop drugH1Div" id="F6273425"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="268855ac-c424-450c-ab52-a51bfe383ea4">Heparin-induced thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia (HIT):</b> Limited data available: <b>Note:</b> Required maintenance dose is highly variable between patients; frequent dosage adjustments required in critically ill patients and/or patients with liver impairment to maintain desired anticoagulant activity.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents ≤16 years: Continuous IV infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose</i>: 0.75 mcg/kg/minute; measure aPTT after 2 hours; titrate to maintain aPTT in desired range; adjust in increments of 0.1 to 0.25 mcg/kg/minute for normal hepatic function; dosing based on population modeling and simulations (Radulescu 2017; Young 2011). <b>Note:</b> A lower initial infusion rate may be needed for critically ill patients and/or patients with liver impairment.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose: </i>Measure aPTT 2 hours after any dose change and at least once daily; more frequent monitoring may be required based on clinical status; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value (depends on bleeding risk), not exceeding 100 seconds; adjust in increments of 0.1 to 0.25 mcg/kg/minute for normal hepatic function; reduce dose in hepatic impairment (Young 2011; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion to oral anticoagulant</i>: Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose. Once combined INR on warfarin and argatroban is &gt;4, stop argatroban. Repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained. Another option is to use factor X levels to monitor the effect of warfarin anticoagulation. When factor X level is &lt;0.3, warfarin is considered therapeutic and at which time argatroban can be discontinued (Alsoufi 2004; Boshkov 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f1c93a4-9f0d-42aa-b239-e77884f28a00">Anticoagulation, mechanical circulatory support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticoagulation, mechanical circulatory support:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ventricular assist device (VAD)</i> (ACTION 2020): Very limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Dosing based on a consensus protocol; goal aPTT range determined by risk of bleeding and thrombosis and postoperative phase of care.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: <i>Initial dose:</i> Continuous IV infusion: 0.5 mcg/kg/minute; consider a lower initial dose in the setting of hepatic dysfunction with baseline elevated INR; titrate to achieve target aPTT (See "Dose Adjustments to Achieve Target aPTT" table); usual dosage range: 1 to 5 mcg/kg/minute; doses up to 8 mcg/kg/minute have been used; maximum adult dose: 10 mcg/kg/minute.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Dose Adjustments to Achieve Target aPTT</b></p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>aPTT</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Argatroban titration</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Time to repeat aPTT<sup>a</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Consider more frequent aPTT monitoring based on clinical scenario.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Round dose up to closest second decimal (hundredth place).</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Recommendation in patient with normal hepatic function; in patients with significant hepatic impairment, hold infusion for 2 hours then recheck aPTT before restarting (see "Dosing: Hepatic Impairment: Pediatric").</p>
<p style="text-indent:0em;text-align:left;">Adapted from ACTION 2020.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥15 to 30 seconds below goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increase infusion by 25%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 to &lt;15 seconds below goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increase infusion by 15%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Within goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No change</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours; then daily after 2 consecutive aPTTs within goal range</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 to &lt;15 seconds above goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Decrease infusion by 15%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥15 to 30 seconds above goal range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Decrease infusion by 25%<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 3 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;3× baseline or &gt;~120 seconds</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hold infusion for 15 minutes and decrease infusion by 30%<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 hours</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064908"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to severe impairment: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; however, based on consensus protocol and adult information, no dosage adjustment necessary (ACTION 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Based on adult information, ~20% argatroban removed over 4 hours during hemodialysis (NCS/SCCM [Frontera 2016]); removal during hemodialysis and continuous venovenous hemofiltration did not alter clinical efficacy when used for anticoagulation in renal replacement therapy (Tang 2005).</p></div>
<div class="block dohp drugH1Div" id="F51064909"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; decreased clearance has been reported in pediatric patients with liver impairment; the dose should be reduced:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heparin-induced thrombocytopenia (HIT): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">AST/ALT ≥3 times ULN:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose: Continuous IV Infusion: Reduce initial dose to 0.2 mcg/kg/minute; measure aPTT after 2 hours and adjust dose to maintain aPTT in the desired range; adjust in increments of ≤0.05 mcg/kg/minute (Young 2011).</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: Measure aPTT 2 hours after any dose change and at least once daily; more frequent monitoring may be required based on clinical status; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value (depends on bleeding risk), not exceeding 100 seconds; adjust in increments of ≤0.05 mcg/kg/minute (Young 2011; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ventricular assist device (VAD):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Continuous IV Infusion (ACTION 2020):</p>
<p style="text-indent:-2em;margin-left:8em;">Baseline liver impairment:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose: Consider dosage reduction if known impairment and baseline elevated INR.</p>
<p style="text-indent:-2em;margin-left:8em;">Liver impairment during treatment:</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: Check aPTT and monitor closely.</p>
<p style="text-indent:-2em;margin-left:8em;">Significant liver impairment during treatment:</p>
<p style="text-indent:-2em;margin-left:10em;">aPTT &gt;3 times baseline or &gt;~120 seconds: Hold infusion for 2 hours then recheck aPTT before restarting.</p></div>
<div class="block doa drugH1Div" id="F136547"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8765" href="/d/html/8765.html" rel="external">see "Argatroban: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="268855ac-c424-450c-ab52-a51bfe383ea4">Heparin-induced thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose:</i> 2 mcg/kg/minute; titrate to maintain aPTT in desired range. <b>Note:</b> Dose adjustment is necessary for critically ill patients and/or patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Critically ill patients</i></b>
<i>:</i> Initial dose: 1 mcg/kg/minute; usual dosing range: 0.25 to 1.5 mcg/kg/minute may be appropriate depending on the level of organ dysfunction (ACCP [Linkins 2012]; Beiderlinden 2007; Kiser 2005; Kiser 2011; Tardy-Poncet 2015).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Usual dosage range for patients with moderate to severe hepatic impairment or heart failure: 0.25 to 0.5 mcg/kg/minute (ACCP [Linkins 2012]; Beiderlinden 2007; Kiser 2005; Kiser 2011; Tardy-Poncet 2015; Yarbrough 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i> Measure aPTT after 2 hours. In critically ill patients, consider measuring aPTT 2 hours after initiation, then every 4 hours to allow for steady state to be achieved. Adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds; dosage should not exceed 10 mcg/kg/minute (Kiser 2011; Tardy-Poncet 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion to oral anticoagulant:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Also consider referring to institutional protocols; optimal approach for conversion to oral therapy has not been established.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Conversion to warfarin:</b> Because there may be a combined effect on the INR when argatroban is used concomitantly with warfarin, loading doses of warfarin should not be used. Initiate warfarin therapy at the expected daily dose. Optimal conversion strategy has not been identified if INR is already &gt;4 on argatroban alone (eg, before starting warfarin); refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving ≤2 mcg/kg/minute of argatroban: Argatroban therapy can be stopped when the INR is &gt;4 on combined warfarin and argatroban therapy; repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.</p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving &gt;2 mcg/kg/minute of argatroban: Reduce dose of argatroban to 2 mcg/kg/minute; measure INR for argatroban and warfarin 4 to 6 hours after dose reduction; argatroban therapy can be stopped when the INR on warfarin and argatroban combined therapy is &gt;4. Repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> The American College of Chest Physicians suggests monitoring chromogenic factor X assay when transitioning from argatroban to warfarin (Garcia 2012) or overlapping administration of warfarin for a minimum of 5 days until INR is within target range; recheck INR after anticoagulant effect of argatroban has dissipated (Guyatt 2012). Factor X levels &lt;45% have been associated with INR values &gt;2 after the effects of argatroban have been eliminated (Arpino 2005).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Conversion to a direct-acting oral anticoagulant:</b> Start direct-acting oral anticoagulant when argatroban infusion is stopped (consult institutional protocol if the aPTT is above the target range) (Dager 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f87074c1-a208-4876-b6cc-70b7276a67a2">Percutaneous coronary intervention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Percutaneous coronary intervention: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i> Begin infusion of 25 mcg/kg/minute and administer bolus dose of 350 mcg/kg (over 3 to 5 minutes). ACT should be checked 5 to 10 minutes after bolus infusion; proceed with procedure if ACT &gt;300 seconds.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Following initial bolus: </i></p>
<p style="text-indent:-2em;margin-left:6em;">ACT &lt;300 seconds: Give an additional 150 mcg/kg bolus, and increase infusion rate to 30 mcg/kg/minute (recheck ACT in 5 to 10 minutes).</p>
<p style="text-indent:-2em;margin-left:6em;">ACT &gt;450 seconds: Decrease infusion rate to 15 mcg/kg/minute (recheck ACT in 5 to 10 minutes).</p>
<p style="text-indent:-2em;margin-left:6em;">Once a therapeutic ACT (300 to 450 seconds) is achieved, infusion should be continued for the duration of the procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If dissection, impending abrupt closure, thrombus formation during PCI, or inability to achieve ACT &gt;300 seconds:</i> An additional bolus of 150 mcg/kg, followed by an increase in infusion rate to 40 mcg/kg/minute may be administered (recheck ACT after each additional bolus or change in infusion rate).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Post-PCI anticoagulation, if required, may be achieved by continuing infusion at a reduced dose of 2 mcg/kg/minute, with close monitoring of aPTT; adjust infusion rate as needed. Recheck ACT after each additional bolus or change in infusion rate.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990327"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV: </b>No dosage adjustment necessary for any degree of kidney dysfunction (Hursting 2008b; Swan 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Bilbao-Meseguer 2018; Udy 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No data; no dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable: Dialytic clearance increases systemic clearance 20% during the procedure without any significant impact on clotting measures (activated clotting time [ACT]) (Murray 2004; Tang 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment or supplemental dose necessary (Hursting 2008b; Murray 2004; Reddy 2005; Tang 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (expert opinion):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary (Reddy 2005; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: IV:</b> No dosage adjustment necessary (Reddy 2005; Tang 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV:</b> No dosage adjustment necessary (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50987669"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Heparin-induced thrombocytopenia:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): There are no specific dosage adjustments provided in the manufacturer's labeling. Use with caution; dosage reduction is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B): Continuous IV infusion: Initial: 0.5 mcg/kg/minute; measure aPTT after 2 hours and adjust dose as needed. In critically ill patients, consider measuring aPTT 2 hours after initiation, then every 4 hours to allow for steady state to be achieved. Adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds (Kiser 2011; Tardy-Poncet 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Continuous IV infusion: Initial: 0.25 mcg/kg/minute; measure aPTT after 2 hours and adjust dose as needed; in critically ill patients, consider measuring aPTT 2 hours after initiation, then every 4 hours to allow for steady state to be achieved. Adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds (Kiser 2011; Yarbrough 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Percutaneous coronary intervention:</i> Avoid use in patients with clinically significant hepatic impairment or elevations of ALT/AST ≥3 × ULN (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F136513"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are reported for adults treated for heparin-induced thrombocytopenia (HIT) and percutaneous coronary intervention with or without heparin-induced thrombocytopenia (PCI), unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (PCI: 15%), hypotension (7% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (major: ≤2%; minor: Including hematemesis: HIT: 14%, PCI: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genitourinary tract hemorrhage (including hematuria; major: HIT: &lt;1%; minor: HIT: 12%, PCI: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (PCI: 4%), angina pectoris (PCI: 2%), brachial artery hemorrhage (minor: HIT: 2%), bradycardia (PCI: 5%), coronary occlusion (PCI: 2%), coronary thrombosis (PCI: 2%), ischemic heart disease (PCI: 2%), ventricular tachycardia (HIT: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3% to 4%), diarrhea (HIT: 6%), nausea (5% to 7%), vomiting (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (major: HIT: &lt;1%; minor: HIT: ≤10%, PCI: ≤2%), decreased hemoglobin (major: HIT: &lt;1%; minor: HIT: ≤10%, PCI: ≤2%), groin bleeding (including hematoma; minor: 4% to 5%), hemorrhage (major hemorrhage: HIT: 5%; minor: PCI [CABG related]: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (PCI: 5%), pain (HIT: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (PCI: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (HIT: 3%), hemoptysis (minor: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aortic valve stenosis (PCI), atrial thrombosis (PCI), vascular disease (PCI)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroesophageal reflux disease (PCI)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation (HIT), retroperitoneal bleeding (PCI)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site (access site: PCI), local hemorrhage (limb and below-the-knee stump: HIT)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular disease (PCI)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema (PCI)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F136527"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to argatroban or any component of the formulation; major bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hereditary fructose intolerance.</p></div>
<div class="block war drugH1Div" id="F136511"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: The most common complication is bleeding and can occur at any site in the body. Use extreme caution in patients with hematologic conditions associated with increased bleeding (eg, congenital or acquired bleeding disorders, GI lesions); recent puncture of large vessels or organ biopsy; spinal anesthesia; immediately following lumbar puncture; recent cerebrovascular accident (CVA), stroke, intracerebral surgery, or other neuraxial procedure; severe hypertension; renal impairment; recent major surgery; recent major bleeding (intracranial, GI, intraocular, or pulmonary). Monitor for signs and symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Airway, skin, and generalized hypersensitivity reactions have been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction is necessary; may require &gt;4 hours to achieve full reversal of anticoagulant effects. Avoid use during PCI in patients with clinically significant hepatic impairment or elevations of ALT/AST ≥3 times ULN (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Critically ill patients: Use with caution in critically-ill patients; reduced clearance may require dosage reduction.</p></div>
<div class="block foc drugH1Div" id="F136522"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/50 mL (50 mL); 250 mg/2.5 mL (2.5 mL); 125 mg/125 mL in NaCl 0.9% (125 mL [DSC]); 50 mg/50 mL in NaCl 0.9% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/50 mL (50 mL); 50 mg/50 mL in NaCl 0.9% (50 mL)</p></div>
<div class="block geq drugH1Div" id="F136507"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F136530"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Argatroban in Sodium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/50 mL 0.9% (per mL): $4.68 - $5.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Argatroban Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/50 mL (per mL): $2.40 - $4.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/2.5 mL (per mL): $114.76 - $244.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865970"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/2.5 mL (2.5 mL)</p></div>
<div class="block adip drugH1Div" id="F53565370"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Molecular weight: 526.66; argatroban is a synthetic anticoagulant (direct thrombin inhibitor) derived from L-arginine. Increases in aPTT, activated clotting time (ACT), PT, INR, and thrombin time (TT) occur in a dose-dependent fashion with increasing doses of argatroban. Adult studies have established the use of aPTT for patients with heparin-induced thrombocytopenia and ACT for patients with percutaneous coronary intervention procedures. Therapeutic ranges for PT, INR, and TT have not been identified.</p>
<p style="text-indent:0em;margin-top:2em;">A reversal agent to argatroban is not available. Should life-threatening bleeding occur, discontinue argatroban immediately, obtain an aPTT and other coagulation tests, and provide symptomatic and supportive care.</p></div>
<div class="block admp drugH1Div" id="F52612260"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Continuous IV infusion: Vials (concentrated solution) must be diluted prior to administration; premixed IV solution (1<b> mg</b>/mL) is available. Administer as a continuous IV infusion with the use of an infusion pump.</p></div>
<div class="block adm drugH1Div" id="F136524"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: The 2.5 mL (100 mg/mL) <b>concentrated</b> vial <b>must be diluted to 1 mg/mL</b> prior to administration. The premixed 50 mL or 125 mL vials and 250 mL bag (1 mg/mL) require no further dilution. The premixed 1 mg/mL vial may be inverted for use with an infusion set. For HIT, administer by continuous IV infusion. For PCI, administer by IV infusion and bolus (over 3 to 5 minutes through a large bore IV line).</p></div>
<div class="block uicp drugH1Div" id="F14471318"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 1 <b>mg</b>/mL.</p></div>
<div class="block sts drugH1Div" id="F136540"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Vials, 2.5 mL (100 mg/mL) concentrate: Prior to use, store vial in original carton at 20°C to 25°C (68°F to 77°F); excursions permitted to 15ºC to 30ºC (59ºF to 86°F). Do not freeze. Protect from light. The prepared solution, diluted in D5W, LR, or NS, is stable for 24 hours at 20°C to 25°C (68°F to 77°F) in ambient indoor light. Do not expose prepared solutions to direct sunlight. Prepared solutions that are protected from light and kept at 20°C to 25°C (68°F to 77°F) or under refrigeration at 2°C to 8°C (36°F to 46°F) are stable for up to 96 hours. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Premixed vials (50 mL or 125 mL) and single-use bags for infusion (1 mg/mL): Store at 20°C to 25°C (68°F to 77°F). Do not refrigerate or freeze. Protect from light. </p></div>
<div class="block usep drugH1Div" id="F53565492"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT) (FDA approved in adults); anticoagulant for percutaneous coronary intervention (PCI) in patients who have or are at risk for HIT (FDA approved in adults); has also been used for anticoagulation in patients with ventricular assist device.</p></div>
<div class="block mst drugH1Div" id="F136573"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Argatroban may be confused with Aggrastat, Orgaran</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">National Patient Safety Goals:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have approved protocols and evidence-based practice guidelines in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes medication selection, dosing (including adjustments for age, renal function, or liver function), drug-drug interactions, drug-food interactions, other applicable risk factors, monitoring, patient and family education, proper administration, reversal of anticoagulation, management of bleeding events, and perioperative management. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism during procedures or hospitalizations (NPSG.03.05.01).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F136560"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F136515"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F136531"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to argatroban in pregnancy is limited. Use of parenteral direct thrombin inhibitors in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt 2012).</p></div>
<div class="block mopp drugH1Div" id="F53565493"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Heparin-induced thrombocytopenia: Obtain baseline aPTT prior to start of therapy. Check aPTT 2 hours after start of therapy and after any dosage adjustment. Monitor hemoglobin, hematocrit, platelets, and signs and symptoms of bleeding. Monitor hepatic function tests at baseline and as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Ventricular assist device (VAD): Monitor aPTTs per dosing recommendations. Monitor hemoglobin, hematocrit, platelets, and signs and symptoms of bleeding. Monitor hepatic function tests at baseline and as clinically indicated.</p></div>
<div class="block rerp drugH1Div" id="F57836262"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Heparin-induced thrombocytopenia (HIT):</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, Children, and Adolescents ≤16 years: Standard aPTT goal: 1.5 to 3 times the baseline aPTT (Young 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Ventricular assist device (VAD):</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Standard aPTT goal: 1.5 to 3 times the baseline aPTT (ACTION 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Consensus protocol has suggested the following aPTT goals based on bleeding risk (ACTION 2020):</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">High risk of bleeding: aPTT: 50 to 60 seconds.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance doses:</p>
<p style="text-indent:-2em;margin-left:10em;">Standard risk: aPTT: 60 to 80 seconds.</p>
<p style="text-indent:-2em;margin-left:10em;">High risk of thrombosis: aPTT: 70 to 90 seconds.</p></div>
<div class="block pha drugH1Div" id="F136510"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A direct, highly-selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation.</p></div>
<div class="block phk drugH1Div" id="F136526"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Immediate </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 174 mL/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Albumin: 20%; alpha<sub>1</sub>-acid glycoprotein: 34% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via hydroxylation and aromatization (major route). Metabolism via CYP3A4/5 (minor route) to four metabolites. Unchanged argatroban is the major plasma component. Plasma concentration of metabolite M1 is 0% to 20% of the parent drug and is three- to five-fold weaker.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 39 to 51 minutes; Hepatic impairment: 181 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Steady-state: 1 to 3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~65%; 14% unchanged); urine (~22%; 16% unchanged); low quantities of metabolites M2-4 in urine</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance:</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Pediatric patients (seriously ill): 0.16 L/kg/hour; 50% lower than healthy adults </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Pediatric patients (seriously ill with elevated bilirubin due to hepatic impairment or cardiac complications; n=4): 0.03 L/kg/hour; 80% lower than pediatric patients with normal bilirubin </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Adult: 0.31 L/kg/hour (5.1 mL/kg/minute); hepatic impairment: 1.9 mL/kg/minute </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539819"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Exembol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Argatra | Argatroban accord</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Argatra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Argatra | Argatroban accord</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Exembol multidose</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arganova</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Novastan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Arganova | Argatroban accord</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Exembol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Novastan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Slonnon Hi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Argatra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Arganova | Arganova multidose</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Argatra</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Argatra</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Novastan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ACTION.1">
<a name="ACTION.1"></a>Advanced Cardiac Therapies Improving Outcomes Network (ACTION). Direct thrombin inhibitor (DTI) harmonization protocol for VADs. https://www.actionlearningnetwork.org. Updated August 24, 2020. Accessed January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15283365">
<a name="15283365"></a>Alsoufi B, Boshkov LK, Kirby A, et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. <i>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</i>. 2004;7:155-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15283365/pubmed" id="15283365" target="_blank">15283365</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed June 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19126826">
<a name="19126826"></a>Ansara AJ, Arif S, Warhurst RD. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia. <i>Ann Pharmacother</i>. 2009;43(1):9-18. doi:10.1345/aph.1L213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/19126826/pubmed" id="19126826" target="_blank">19126826</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Argatroban 250 mg per 250 mL [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; August 2017.</div>
</li>
<li>
<div class="reference">
                  Argatroban injection 125 mg per 125 mL dextrose [prescribing information]. Princeton, NJ: Sandoz Inc; April 2019.</div>
</li>
<li>
<div class="reference">
                  Argatroban injection 250 mg per 2.5 mL [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; July 2019.</div>
</li>
<li>
<div class="reference">
                  Argatroban injection 50 mg per 50 mL (1 mg per mL) [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; March 2021.</div>
</li>
<li>
<div class="reference">
                  Argatroban injection [prescribing information]. Eatontown, NJ: Hikma Pharmaceuticals USA Inc; January 2020.</div>
</li>
<li>
<div class="reference">
                  Argatroban injection [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; April 2020.</div>
</li>
<li>
<div class="reference">
                  Argatroban solution 50 mg per 50 mL [prescribing information]. Princeton, NJ: Sandoz Inc; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767231">
<a name="15767231"></a>Arpino PA, Demirjian Z, and Van Cott EM, “Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin,” <i>Pharmacotherapy</i>, 2005, 25(2):157-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15767231/pubmed" id="15767231" target="_blank">15767231</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Baghdasarian SB, Singh I, Militello MA, et al, “Argatroban Dosage in Critically Ill Patients With HIT,” <i>Blood </i> 2004, 104:1779 [abstract 1779 from 2004 ASH Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17440009">
<a name="17440009"></a>Beiderlinden M, Treschan TA, Gorlinger K, et al. Argatroban anticoagulation in critically ill patients. <i>Ann Pharmacother.</i> 2007;41(5):749-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/17440009/pubmed" id="17440009" target="_blank">17440009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16731103">
<a name="16731103"></a>Boshkov LK, Kirby A, Shen I, et al. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. <i>Ann Thorac Surg.</i> 2006;81(6):S2355-S2359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/16731103/pubmed" id="16731103" target="_blank">16731103</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dager WE, Gulseth MP, Nutescu EA, eds. <i>Anticoagulation Therapy: A Clinical Practice Guide.</i> 2nd ed. American Society of Health-System Pharmacists; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12783589">
<a name="12783589"></a>Dager WE, White RH. Pharmacotherapy of heparin-induced thrombocytopenia. <i>Expert Opin Pharmacother.</i> 2003;4(6):919-940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/12783589/pubmed" id="12783589" target="_blank">12783589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12921506">
<a name="12921506"></a>de Denus S and Spinler SA, “Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca,” <i>Ann Pharmacother</i>, 2003, 37(9):1237-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/12921506/pubmed" id="12921506" target="_blank">12921506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29367082">
<a name="29367082"></a>Elagizi S, Davis K. Argatroban dosing in obesity. <i>Thromb Res</i>. 2018;163:60-63. doi:10.1016/j.thromres.2018.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/29367082/pubmed" id="29367082" target="_blank">29367082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315264">
<a name="22315264"></a>Garcia DA, Baglin TP, Weitz JI, et al, “Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/22315264/pubmed" id="22315264" target="_blank">22315264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18574259">
<a name="18574259"></a>Hirsh J, Guyatt G, Albers GW, et al, “Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” <i>Chest</i>, 2008, 133(6 Suppl):71-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/18574259/pubmed" id="18574259" target="_blank">18574259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15581266">
<a name="15581266"></a>Honisko ME, Fink JM, Militello MA, et al, “Compatibility of Argatroban With Selected Cardiovascular Agents,” <i>Am J Health Syst Pharm</i>, 2004, 61(22):2415-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15581266/pubmed" id="15581266" target="_blank">15581266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17530465">
<a name="17530465"></a>Hursting MJ, Jang IK. Effect of body mass index on Argatroban therapy during percutaneous coronary intervention. <i>J Thromb Thrombolysis</i>. 2008a;25(3):273-279. doi:10.1007/s11239-007-0051-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/17530465/pubmed" id="17530465" target="_blank">17530465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18560242">
<a name="18560242"></a>Hursting MJ, Murray PT. Argatroban anticoagulation in renal dysfunction: a literature analysis. <i>Nephron Clin Pract</i>. 2008b;109(2):c80-c94. doi:10.1159/000139993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/18560242/pubmed" id="18560242" target="_blank">18560242</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. <i>Pharmacotherapy</i>. 2005;25(12):1736-1745. doi:10.1592/phco.2005.25.12.1736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/16305293/pubmed" id="16305293" target="_blank">16305293</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kiser TH, Mann AM, Trujillo TC, Hassell KL. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. <i>Am J Hematol.</i> 2011;86(3):267-272. doi:10.1002/ajh.21955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/21328434/pubmed" id="21328434" target="_blank">21328434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16685006">
<a name="16685006"></a>Levine RL, Hursting MJ, and McCollum D, "Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction," <i>Chest</i>, 2006, 129(5):1167-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/16685006/pubmed" id="16685006" target="_blank">16685006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12357516">
<a name="12357516"></a>Lewis BE, Matthai WH, Cohen M, et al, “Argatroban Anticoagulation During Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia,” <i>Catheter Cardiovasc Interv</i>, 2002, 57(2):177-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/12357516/pubmed" id="12357516" target="_blank">12357516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11294800">
<a name="11294800"></a>Lewis BE, Wallis DE, Berkowitz SD, et al, “Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia,” <i>Circulation</i>, 2001, 103(14):1838-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/11294800/pubmed" id="11294800" target="_blank">11294800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19050602">
<a name="19050602"></a>Link A, Girndt M, Selejan S, et al, “Argatroban for Anticoagulation in Continuous Renal Replacement Therapy,” <i>Crit Care Med</i>, 2009, 37(1):105-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/19050602/pubmed" id="19050602" target="_blank">19050602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins L, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest. </i>2012;141(2)(suppl):e495-e530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15569338">
<a name="15569338"></a>Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. <i>Kidney Int</i>. 2004;66(6):2446-2453. doi:10.1111/j.1523-1755.2004.66022.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15569338/pubmed" id="15569338" target="_blank">15569338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28346967">
<a name="28346967"></a>Radulescu VC. Anticoagulation therapy in children. <i>Semin Thromb Hemost</i>. 2017;43(8):877-885. doi:10.1055/s-0036-1598004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/28346967/pubmed" id="28346967" target="_blank">28346967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16131539">
<a name="16131539"></a>Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. <i>Ann Pharmacother.</i> 2005;39(10):1601-1605. doi:10.1345/aph.1G033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/16131539/pubmed" id="16131539" target="_blank">16131539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12708939">
<a name="12708939"></a>Reichert MG, MacGregor DA, Kincaid EH, et al, “ Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia,” <i>Ann Pharmacother</i>, 2003, 37(5):652-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/12708939/pubmed" id="12708939" target="_blank">12708939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17525167">
<a name="17525167"></a>Rice L, Hursting MJ, Baillie GM, McCollum DA. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. <i>J Clin Pharmacol</i>. 2007;47(8):1028-1034. doi:10.1177/0091270007302951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/17525167/pubmed" id="17525167" target="_blank">17525167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10730687">
<a name="10730687"></a>Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. <i>Pharmacotherapy</i>. 2000;20(3):318-329. doi:10.1592/phco.20.4.318.34881<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/10730687/pubmed" id="10730687" target="_blank">10730687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15632219">
<a name="15632219"></a>Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. <i>Ann Pharmacother</i>. 2005;39(2):231-236. doi:10.1345/aph.1E480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15632219/pubmed" id="15632219" target="_blank">15632219</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tardy-Poncet B, Nguyen P, Thiranos JC, et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. <i>Crit Care.</i> 2015;19:396. doi:10.1186/s13054-015-1109-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/26556106/pubmed" id="26556106" target="_blank">26556106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/26556106/pubmed" id="26556106" target="_blank">26556106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23073302">
<a name="23073302"></a>Yarbrough PM, Varedi A, Walker A, et al. Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by Child-Pugh class C liver disease. <i>Ann Pharmacother.</i> 2012;46(11):e30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/23073302/pubmed" id="23073302" target="_blank">23073302</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Young G and Boshkov L. Prospective study of direct thrombin inhibition with argatroban in pediatric patients requiring non-heparin anticoagulation. <i>Blood</i>. 2007; 110.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21488155">
<a name="21488155"></a>Young G, Boshkov LK, Sullivan JE, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. <i>Pediatr Blood Cancer</i>. 2011;56(7):1103-1109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/21488155/pubmed" id="21488155" target="_blank">21488155</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13081 Version 285.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
